MIKEL ZAMORA: Open Payments
NPI 1518943224 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,312 in 176 payments from 15 companies in 2025. Trend: 2023 $2,833 · 2024 $3,123 · 2025 $3,312
Food & beverage: $3,312
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $461 |
| Janssen Biotech, Inc. | 16 | $340 |
| QOL Medical, LLC | 12 | $328 |
| Celltrion USA Inc. | 23 | $325 |
| ABBVIE INC. | 15 | $323 |
| Gilead Sciences, Inc. | 8 | $252 |
| Madrigal Pharmaceuticals | 10 | $227 |
| Aimmune Therapeutics, Inc. | 16 | $224 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 27 | $213 |
| Ipsen Biopharmaceuticals, Inc | 7 | $179 |
Products named: TREMFYA, Sucraid, VEGZELMA, ENTYVIO, REZDIFFRA, RINVOQ, ZENPEP, IQIRVO.
Industry payments across TX — which companies pay providers there.
